Abatacept FDA Link

A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.

Also Known As:

Orencia; BMS 188667; BMS-188667; BMS-224818; BMS224818; Belatacept; CTLA-4-Ig; CTLA4-Fc; CTLA4-Ig; CTLA4-Ig Immunoconjugate; Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin; LEA29Y; Nulojix; BMS 224818; BMS188667; CTLA4 Ig Immunoconjugate; Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin; Immunoconjugate, CTLA4-Ig

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoconjugates: 3432
        Abatacept: 1362
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoconjugates: 3432
        Abatacept: 1362

D Moniz Reed Selected Research

D Moniz Reed Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure